Abstract 3930
Background
Tepotinib is an oral, selective, potent MET tyrosine kinase inhibitor, with promising clinical activity in patients (pts) with MET+ tumors, being tested in NSCLC harboring METex14 mutations or MET amplification. We aimed to further characterize the safety profile of tepotinib.
Methods
Safety data from pts receiving tepotinib 500 mg once daily (QD) from five studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) were pooled and summarized. Pts received tepotinib until disease progression, intolerable toxicity, or other withdrawal. Adverse events (AEs) were graded by NCI CTCAE v4.03.
Results
As of 9/28/2018, 422 pts had received tepotinib; 228 received 500 mg tepotinib monotherapy QD and were further analyzed for safety (73.2% male, 50.9%/35.5% white/Asian, median age 65.0 [range 19–89] yrs). Median treatment duration was 2.7 months (range 0.0–21.5); in NSCLC pts with METex14 mutations it was 4.1 months (NCT02864992). 219 pts (96.1%) had an AE (any cause). 122 pts (53.5%) had a Grade ≥3 any cause AE including (>3.5%): disease progression (n = 18, 7.9%), hyponatremia (n = 12, 5.3%), increased aspartate aminotransferase (AST) (n = 12, 5.3%), increased lipase (n = 11, 4.8%), peripheral edema (n = 9, 3.9%) and ascites (n = 9, 3.9%). The incidence rates were: 19.0, 12.9, 12.9, 12.0, 9.6 and 9.6 per 100 pt-years, respectively. Treatment-related (TR)AEs are shown in the Table. 18 pts (7.9%) had a serious TRAE including (≥1%) peripheral edema (n = 4, 1.8%). AEs (any cause) led to dose reduction of tepotinib in 33 pts (14.5%) and discontinuation in 49 pts (21.5%), and was due to peripheral edema in 5 (8.5%) and 7 (3.1%) pts, respectively. Of 25 AEs leading to death, two were considered treatment related by the investigator (upper GI hemorrhage and hypoglycemic coma).
Conclusions
Tepotinib demonstrated an acceptable safety profile across a range of tumor types and is being developed in NSCLC as monotherapy and in combination. Further characterization of peripheral edema is ongoing.Table:
479P
N = 228 | ||
---|---|---|
Any Grade (≥10%) | Grade ≥3 (≥2%) | |
Any TRAE, n (%) | 172 (75.4) | 52 (22.8) |
Peripheral edema | 77 (33.8) | 8 (3.5) |
Diarrhea | 45 (19.7) | 4 (1.8) |
Fatigue | 34 (14.9) | 3 (1.3) |
Nausea | 29 (12.7) | 0 (0) |
Decreased appetite | 27 (11.8) | 0 (0) |
Increased lipase | 13 (5.7) | 9 (3.9) |
Increased AST | 11 (4.8) | 5 (2.2) |
Clinical trial identification
NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.
Editorial acknowledgement
Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Matthew deSchoolmeester, PhD of Bioscript Science (Macclesfield, UK).
Legal entity responsible for the study
Merck KGaA.
Funding
Merck KGaA.
Disclosure
T. Decaens: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: IPSEN; Honoraria (self), Travel / Accommodation / Expenses: Gilead; Honoraria (self), Travel / Accommodation / Expenses: Abbvie; Honoraria (self): Sanofi; Advisory / Consultancy: SITEX; Research grant / Funding (institution): ArQule; Research grant / Funding (institution): Genoscience Pharma; Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: BTG; Advisory / Consultancy: Sirtex. R. Veillon: Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Merck. K. Yamazaki: Honoraria (self): Chugai; Honoraria (self): Takeda; Honoraria (self): Yakult; Honoraria (self): Daiichi‐sankyo; Honoraria (self): Merck Serono; Honoraria (self): Bristol; Honoraria (self): Bayer; Honoraria (self): Eli Lilly; Honoraria (self): Taiho; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Sanofi. J. Scheele: Full / Part-time employment: Merck KGaA. R. Bruns: Full / Part-time employment: Merck KGaA. K. Berghoff: Full / Part-time employment: Merck KGaA. S. Faivre: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Blueprint; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer Pharma; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis. P.P. Paik: Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Abbvie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: EMD Serono; Honoraria (self): Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract